Merck Sharp + Dohme Corp.

Kallyope, Inc.

Msd Italia S.r.l.

Merck + Co., Inc.

Albany Molecular Research, Inc.

Shuwen He

Liangqin Guo

Ravi P Nargund

Yongxin Han

Anandan Palani

Peng Li

Dong Xiao

Xing Dai

Xuanjia Peng

Nicolas Zorn

Joseph A Kozlowski

Alexander Pasternak

Wensheng Yu

Casey Cameron McComas

Hongjun Zhang

Iyassu Sebhat

Hong Liu

Richard Soll

Xavier Fradera

Dane James Clausen

Qinglin Pu

Zhong Lai

Qun Dang

Kun Liu

Li Xiao

Jared N Cumming

Guoqing Li

Nigel J Liverton

Hao Wu

Xianhai Huang

Jian Liu

Derun Li

Abdelghani Achab

Ping Chen

Frank Narjes

Uwe Koch

Joerg Habermann

Feng Ye

Theodore A Martinot

Barbara A Pio

Michael W Miller

Wen-Lian Wu

Shawn P Walsh

Purakkattle J Biju

Harry R Chobanian

Yongqi Deng

Zhixiong Ye

Linda Brockunier

Clare London

Quang T Truong

Jinsong Hao

Tianying Jian

Rui Zhang

Christopher R Moyes

Karen M Marcantonio

Peter H Dobbelaar

Hua Zhou

Andrew William Stamford

Tesfaye Biftu

William K Hagmann

Shrenik K Shah

Tao Guo

Jack D Scott

Peter Guzzo

Jongwon Lim

Feroze Ujjainwalla

David L Sloman

Jonathan R Young

Zhi-Cai Shi

Raman Kumar Bakshi

Nunzio Sciammetta

Linus S Lin

Santhosh Francis Neelamkavil

Yan Guo

Meredeth Ann McGowan

Brandon Mitsuo Taoka

Bruce Sargent

Alan John Henderson

Christopher L Franklin

Mark Hadden

Iyassu K Sebhat

Andreas Verras

Ravi Kurukulasuriya

Qingmei Hong

Allan James Goodman

Timothy A Cernak

Cheng Guo

Yingjie Lai

Larry Yet

James Dellureficio

Megan Ruenz

Lisa Krug

Ann Weber

Brett Lauring

Nancy Thornberry

Paul Richards

Scott B Joseph

The present disclosure relates to compounds useful as modulators of neurokinin receptor 3 (NK3) for the treatment of conditions or disorders.

NK3 modulators and uses thereof

This disclosure is directed, at least in part, to GPR40 agonists useful for the treatment of conditions or disorders involving the gut-brain axis. In some embodiments, the GPR40 agonists are gut-restricted compounds. In some embodiments, the GPR40 agonists are full agonists or partial agonists. In some embodiments, the condition or disorder is a metabolic disorder, such as diabetes, obesity, nonalcoholic steatohepatitis (NASH), or a nutritional disorder such as short bowel syndrome.

GPR40 agonists

Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

Substituted piperazine amide compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors

Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

Arylalkyl pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors

Substituted pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors

This disclosure is directed, at least in part, to AMPK activators useful for the treatment of conditions or disorders associated with AMPK. In some embodiments, the condition or disorder is associated with the gut-brain axis. In some embodiments, condition or disorder is associated with systemic infection and inflammation from having a leaky gut barrier. In some embodiments, the AMPK activators are gut-restricted compounds. In some embodiments, the AMPK activators are agonists or partial agonists.

AMPK activators

This disclosure is directed, at least in part, to GPR119 agonists useful for the treatment of conditions or disorders involving the gut-brain axis. In some embodiments, the GPR119 agonists are gut-restricted compounds. In some embodiments, the condition or disorder is a metabolic disorder, such as diabetes, obesity, nonalcoholic steatohepatitis (NASH), or a nutritional disorder such as short bowel syndrome.

GPR119 agonists

Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder. 

[1.1.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors

This disclosure is directed, at least in part, to AMPK activators useful for the treatment of conditions or disorders associated with AMPK. In some embodiments, the condition or disorder is associated with the gut-brain axis. In some embodiments, condition or disorder is associated with systemic infection and inflammation from having a leaky gut barrier. In some embodiments, the AMPK activators are gut-restricted compounds. In some embodiments, the AMPK activators are agonists, super agonists, full agonists, or partial agonists.

Substituted [1.1.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors

[3.3.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia. 

Antidiabetic heterocyclic compounds

Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof. Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder. 

Substituted N'-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase IDO inhibitors

Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: Formula (I). Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder. 

Substituted n'-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors

Growing community of inventors

Fanwood, NJ, United States of America

Shuwen He